IRL-1620 (TFA)

$120$360

Products Details

Product Description

– IRL-1620 (TFA) is a potent and selective endothelin receptor type B (ETB) agonist with a Ki of 16 pM[1].

Web ID

– HY-16465A

Storage Temperature

– -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)

Shipping

– Blue Ice

Applications

– Neuroscience-Neurodegeneration

Molecular Formula

– C88H118F3N17O29

References

– [1]Takai M, et al. A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor. Biochem Biophys Res Commun. 1992 Apr 30;184(2):953-9.|[2]Briyal S, et al. Stimulation of endothelin B receptors by IRL-1620 decreases the progression of Alzheimer’s disease. Neuroscience. 2015 Aug 20;301:1-11.

Molecular Weight

– 1934.97

Compound Purity

– 99.68

SMILES

– C(C(O)=O)(F)(F)F.C([C@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CN=CN1)NC([C@@H](NC([C@@H](NC([C@H](CC2=CC=C(O)C=C2)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CCC(O)=O)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)C)=O)C(C)C)=O)=O)CC3=CC=CC=C3)=O)C)=O)=O)CC(C)C)=O)CC(O)=O)=O)[C@H](CC)C)=O)[C@H](CC)C)=O)C(O)=O)C=4C=5C(NC4)=CC=CC5

Clinical Information

– No Development Reported

Research Area

– Neurological Disease; Endocrinology

Solubility

– DMSO : 50 mg/mL (ultrasonic)

Target

– Endothelin Receptor

Isoform

– ETB

Pathway

– GPCR/G Protein

Product type

– Peptides

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=